There is no single average mass tort settlement amount. Across active and recently resolved litigations in 2026, per-claimant settlement amounts most often land between $20,000 and $500,000, with a practical blended planning figure of roughly $150,000 to $200,000 per compensable claim. High-volume dockets pull the average down hard: the $6.01 billion 3M Combat Arms earplug program works out to roughly $22,000 per case. Catastrophic-injury dockets pull it up: mesothelioma claims are commonly reported between $1 million and $1.4 million, and Camp Lejeune Elective Option offers are fixed at $100,000 to $550,000 with approved offers averaging about $294,000.
The number that matters is never the headline average. It is the value of your tier inside that litigation's settlement matrix, after fees, holdbacks and liens.
Why "Average Mass Tort Settlement Amount" Is the Wrong Question
Mass tort settlement amounts are not distributed around a mean. They are distributed in tiers, and the tiers are separated by an order of magnitude. A settlement program that pays $7,000 for undocumented tinnitus and $750,000 for severe verified bilateral hearing loss does not have a meaningful "average" in any useful sense, even though the arithmetic mean sits near $22,000.
That matters for two different audiences. Claimants searching for a mass tort payout figure are usually trying to answer a binary question: is filing worth it. Law firms evaluating a docket are trying to answer a very different one: what does a compensable case in this litigation project to be worth, and what does it cost to acquire one.
This report answers both. Everything below is organized around the four variables that actually move a settlement number: injury tier, documentation strength, exposure or usage proof, and the venue and negligence rules governing the claim.
Mass Tort Settlement Amounts by Tort (2026)
The table below reflects the state of each litigation as of September 2026. Where a global settlement exists, the figures are drawn from the announced fund and publicly reported program structure. Where no settlement exists, the figures are attorney and industry projections based on comparable dockets, bellwether outcomes and settlement matrices in analogous litigations, and should be read as estimates rather than entitlements.
| Litigation | Status (Sept 2026) | Reported / projected range per claimant | Working average |
|---|---|---|---|
| Mesothelioma / Asbestos | Ongoing trust + tort recovery; mature | $400,000 – $2,400,000+ | ~$1,200,000 |
| J&J Talc (ovarian) | $5.5B proposed July 27, 2026; needs 95% claimant participation; ~76,000 claims | $100,000 – $1,000,000 (industry estimate) | ~$500,000* |
| Camp Lejeune (CLJA) | Elective Option live; ~$968M offered / ~$801M paid as of July 2026 | $100,000 – $550,000 (fixed grid) | ~$294,000 |
| Depo-Provera (meningioma) | Master Settlement Agreement signed July 21, 2026; terms confidential; ~80% of MDL plaintiffs eligible | $75,000 – $1,500,000 (attorney estimates) | ~$150K – $500K |
| AFFF / PFAS (personal injury) | No global PI settlement; ~15,000+ pending; water-system deals resolved | $20,000 – $500,000+ (tiered projection) | ~$250K – $450K |
| Roundup (glyphosate) | $7.25B class settlement proposed Feb 2026; SCOTUS ruled for Bayer in Monsanto v. Durnell, June 25, 2026 | $5,000 – $250,000+ historically; tier ceiling ~$165,000 | ~$100K – $165K |
| Hair Relaxer | No settlement; bellwether track advancing toward trial | $100,000 – $500,000 (projection) | ~$300K |
| NEC Infant Formula | $495M bellwether verdict against Abbott; settlement talks ongoing | $150,000 – $1,000,000+ (projection) | ~$400K |
| Philips CPAP | ~$1.1B framework ($479M economic loss + $600M+ personal injury); windows closed | Low four figures (economic loss) to six figures (cancer tier) | ~$100K (PI tier) |
| Bard / BD Hernia Mesh | $1B+ resolving ~38,000 claims; administration ongoing | $10,000 – $100,000+ | ~$26,000 |
| GLP-1 (Ozempic, Mounjaro) | MDL 3094 growing fast; bellwether selection underway; no settlement | $50,000 – $500,000 (speculative) | Not yet establishable |
| 3M Combat Arms Earplugs | $6.01B fund, 2023–2029; $3.06B+ distributed as of Feb 2026 | $5,000 – $300,000+ (EIF awards higher) | ~$22,000 |
*See the next section on why the talc "$500,000 average" and the $5.5 billion fund cannot both be true for all 76,000 claimants. Figures compiled from JPML statistical reports, DOJ status filings in E.D.N.C., MDL court records, and published attorney estimates. Estimates are not guarantees and no outcome is promised.
Fund Math vs. Advertised Averages: The Number Most Pages Get Wrong
Almost every page ranking for mass tort settlement amounts quotes two figures side by side without reconciling them: the total settlement fund, and a per-claimant "average" that is far larger than the fund divided by the claim count. Both cannot be right.
Run the arithmetic on the 2026 talc settlement. A $5.5 billion fund across roughly 76,000 ovarian cancer claims is about $72,000 per claim before attorney fees, common benefit holdbacks and administration costs. The widely circulated $500,000 average reflects what a strong, well-documented, high-tier claim may be worth inside the matrix, not what a typical claimant receives. The gap between those two numbers is the entire story of mass tort valuation: a minority of claims consume the majority of the fund.
Divide the announced fund by the claim count to get the ceiling on the blended average. Treat any advertised per-claimant figure above that number as a description of the top tier, not the middle. In most matrices, the top two tiers take 55–70% of the fund while representing 15–25% of claimants.
The same test applied elsewhere: 3M's $6.01 billion across roughly 260,000 claims lands near $23,000, which is close to the reported ~$22,000 average, so that program's headline number is honest. Bard hernia mesh at $1 billion across ~38,000 claims lands near $26,000. Camp Lejeune is the cleanest case of all because the Elective Option is a published grid rather than an estimate, with Tier 1 bands at $150,000 / $300,000 / $450,000 and Tier 2 bands at $100,000 / $250,000 / $400,000 depending on exposure length.
How Mass Tort Settlement Amounts Are Actually Calculated
Once a global settlement is reached, individual amounts are almost never negotiated one by one. A settlement administrator applies a settlement matrix, which converts a claim file into a score and the score into a dollar figure. Understanding the matrix explains almost all of the variation you see in published ranges.
1. Base value by injury tier
Every program opens with a tier assignment driven by diagnosis. In AFFF, kidney and testicular cancer sit above thyroid disease and ulcerative colitis. In CPAP, cancer diagnoses were weighted highest because the FDA confirmed degraded PE-PUR foam could release carcinogens. In Depo-Provera, tumor grade and whether surgical resection was required is expected to drive the tiering.
2. Multipliers and point adjustments
The base value then moves, typically within a band of roughly 80% to 120%, based on:
- Exposure or usage duration — years of documented product use, or in Camp Lejeune, months stationed on base.
- Age at diagnosis — younger claimants generally score higher because lost life-years and lost earnings are larger.
- Treatment intensity — surgery, radiation, chemotherapy and permanent impairment all raise the score.
- Economic damages — documented medical spend and verifiable lost income.
- Alternative-cause factors — smoking history, family history, genetic markers and other exposures can reduce the score.
- Documentation completeness — the single most controllable variable, and the one that kills the most claims.
3. Deductions off the top
Common benefit holdbacks for plaintiffs' leadership come out before individual distribution. The 3M program used a 9% holdback, which equated to roughly $540 million. Healthcare liens, Medicare and Medicaid recovery, and case costs are resolved before the claimant is paid.
In most 2026 programs, the difference between a mid-tier and a top-tier award is not the severity of the injury. It is whether the file proves it. Medical records establishing both the exposure and the diagnosis, with dates that line up, routinely move a claim by six figures. This is why claim verification and record retrieval have become the highest-leverage spend in a mass tort practice.
What a Claimant Actually Takes Home
Gross settlement amounts are what gets advertised. Net recovery is what gets received. The stack looks like this on a hypothetical $250,000 gross award:
| Line item | Typical amount | Running balance |
|---|---|---|
| Gross settlement award | — | $250,000 |
| Common benefit holdback (9%) | −$22,500 | $227,500 |
| Contingency fee (33.3% of gross) | −$83,250 | $144,250 |
| Case costs & record retrieval | −$1,500 to $5,000 | ~$140,000 |
| Healthcare / Medicare liens | Highly variable | $100,000 – $140,000 |
Illustrative only. Fee agreements, holdback percentages and lien resolution differ by litigation and by firm. Nothing here is legal, tax or financial advice.
A useful rule: plan on a claimant netting 50% to 62% of the gross award before liens, and less after. This is why a tiered program that looks generous in headline terms can still disappoint claimants who expected the advertised number.
Mass Tort Settlement Amounts by State Negligence Law
State law does not set mass tort settlement amounts directly, but it shapes them. Comparative negligence rules determine whether a partially at-fault claimant recovers anything at all, statutes of limitation and repose determine whether the claim exists, and venue jury history determines the trial risk that both sides price into settlement.
| Negligence rule | How it works | States |
|---|---|---|
| Pure comparative negligence | Recovery is allowed even if the claimant is mostly at fault. At 90% responsible, 10% of damages remain recoverable. | Alaska, Arizona, California, Florida, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, New York, Rhode Island, Washington |
| Modified comparative (50% bar) | No recovery once the claimant is 50% or more responsible. | Arkansas, Colorado, Georgia, Idaho, Kansas, Maine, Nebraska, North Dakota, Tennessee, Utah |
| Modified comparative (51% bar) | Recovery is allowed at exactly 50% responsibility, barred at 51% or more. | Connecticut, Delaware, Hawaii, Illinois, Indiana, Iowa, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire, New Jersey, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, Vermont, West Virginia, Wisconsin, Wyoming |
Blended across the torts in our dataset, settlement values track those rules in the direction you would expect. Pure comparative negligence jurisdictions support the highest blended values because fewer claims are extinguished by allocation of fault, and because several of those states also house historically plaintiff-favorable venues.
| Negligence rule | Claim survival profile | Blended avg. settlement |
|---|---|---|
| Pure comparative negligence | Highest — partial fault reduces but does not bar recovery | $389,629 |
| Modified comparative (50% bar) | Moderate — claims at or above half fault are extinguished | $258,085 |
| Modified comparative (51% bar) | Moderate — marginally more permissive than the 50% bar | $242,185 |
Blended averages reflect our own analysis across resolved and projected tort values weighted by state filing volume. State law is one input among many; product identification, venue and injury tier matter more.
How Long Mass Tort Settlement Payouts Take
Firms and claimants consistently underestimate this. A realistic 2026 timeline:
- Filing to MDL consolidation: 3 to 12 months.
- Pretrial, Daubert and bellwether selection: 18 to 36 months. This is where dockets die. The federal Zantac MDL was gutted by an expert-evidence ruling, and Roundup's leverage shifted materially after the Supreme Court's June 2026 decision in Monsanto v. Durnell.
- Global settlement negotiation: 6 to 18 months after a credible bellwether signal.
- Registration, scoring and first payments: 6 to 18 months after signing. Depo-Provera's master agreement was signed in July 2026 with registration targeted for November 2026 and first payments projected into 2027.
- Full distribution: multi-year. 3M's settlement was announced in August 2023 and was still releasing deferred-program funds in 2026, with contributions scheduled through 2029.
For a firm, the practical implication is that case acquisition spend precedes fee revenue by 24 to 48 months. That gap, not the settlement value, is what most often breaks a mass tort program. It is also why litigation funding is a standard part of the capital stack for firms scaling a docket.
Mass Tort vs. Class Action Settlement Amounts
The two get conflated constantly, and the difference is the single biggest driver of payout size.
| Mass tort / MDL | Class action | |
|---|---|---|
| Claim structure | Each plaintiff files an individual lawsuit | One representative sues for the class |
| Damages | Valued individually by tier and evidence | Common fund divided among members |
| Typical individual recovery | Tens of thousands to seven figures | Frequently $10 to $500 |
| Evidence burden | Individual causation and damages required | Minimal for absent class members |
| Lead qualification | Strict: product use + diagnosis + timeliness | Broad |
This distinction is why mass tort lead qualification is so much more rigorous, and why mass tort leads cost an order of magnitude more than consumer class action leads. Each claimant has to independently prove a case.
Docket ROI: What Settlement Amounts Mean for a Law Firm
For a plaintiff firm, the settlement amount is one of four numbers, and by itself it is the least useful. Return on a mass tort program is determined by:
- Cost per signed retainer (CPR), not cost per lead. A vendor selling 200 leads at $95 each has sold you $19,000 of inventory. If intake signs 22 and three fall off at medical record verification, you have 19 retained cases and a true CPR near $1,000.
- Compensable rate — the share of signed cases that survive records review, criteria tightening and statute deadlines. Falloff of 13% to 20% is normal.
- Projected gross per compensable case — the tier-weighted expected value, not the advertised top tier.
- Fee net of holdback — contingency percentage minus common benefit assessment.
2026 acquisition benchmarks
| Channel / tort | Cost per qualified lead | Cost per signed retainer |
|---|---|---|
| Paid social (blended) | $80 – $300 | $350 – $1,200 |
| Google Search (high intent) | $150 – $600 | $600 – $2,000 |
| Talc / AFFF (mature, competitive) | $150 – $400 | $1,500 – $4,000 |
| Roundup | $300 – $400 | $2,800 – $3,500 |
| AFFF firefighting foam | $250 – $350 | $2,000 – $2,600 |
| Depo-Provera | $95 – $180 | $900 – $1,800 |
| GLP-1 (Ozempic, Mounjaro) | $35 – $65 | $500 – $800 |
| Signed-retainer purchase (done-for-you) | N/A | $1,500+ |
Ranges reflect published 2026 market benchmarks across multiple agencies and vendors. Actual pricing varies by geography, criteria tightness, docket maturity and exclusivity. See current campaign pricing for our numbers.
Risk-adjusted return, not gross multiple
Most ROI figures published in this industry are gross and therefore useless. A Depo-Provera case acquired at $1,400 with a projected $250,000 gross settlement and a 33.3% fee looks like a 59x return. That number ignores everything that happens in between. A defensible model applies three haircuts:
- Compensable rate: assume 50–60% of signed cases ultimately qualify and get paid.
- Common benefit holdback: 6–9% off the top.
- Carry cost: 24–48 months of capital at your cost of funds, plus per-case costs of $300 to $600.
Run through that filter, the same case projects to roughly $41,000 to $48,000 of net fee per signed case — still strong, but roughly 30x rather than 59x, and dependent on a settlement that had not been publicly priced as of September 2026. That is the honest version of the math, and it is the version a firm should underwrite against.
Mass Tort Campaign ROI Calculator
Enter your own assumptions. The calculator applies the compensable-rate and holdback haircuts described above.
Model your docket
Model only. Excludes cost of capital, case costs, staffing and overhead. Projected settlement values are estimates and no outcome is guaranteed.
Sources & Methodology
Case counts are taken from Judicial Panel on Multidistrict Litigation statistical reports, which showed 203,915 pending actions across 162 active dockets in the July 2026 report. Camp Lejeune figures come from Department of Justice status filings in the Eastern District of North Carolina. Settlement fund sizes are drawn from company announcements and court records: J&J's $5.5 billion talc proposal announced July 27, 2026; 3M's $6.01 billion Combat Arms contribution scheduled 2023–2029; Philips Respironics' ~$1.1 billion framework; Becton Dickinson's $1 billion-plus hernia mesh resolution.
Per-claimant ranges for unsettled dockets are attorney and industry projections compiled from multiple published sources and cross-checked against fund-to-claim arithmetic where a fund exists. Where published averages conflict with fund math, we flag the conflict rather than repeating the larger number. Acquisition benchmarks are compiled from published 2026 agency and vendor market data and reconciled against our own campaign performance.
Case counts, settlement terms and trial dates in mass tort litigation change monthly. This page is reviewed and updated on a rolling basis; the date at the top reflects the most recent review.
Mass Tort Settlement Amounts: FAQ
What is the average mass tort settlement amount?
There is no single national average. Per-claimant amounts in 2026 most commonly fall between $20,000 and $500,000. A blended planning figure of $150,000 to $200,000 is reasonable, but it conceals enormous variation: the 3M earplug program averages around $22,000 while mesothelioma claims commonly report between $1 million and $1.4 million.
How much does a mass tort pay per person in 2026?
It depends entirely on the settlement matrix for that litigation. Camp Lejeune Elective Option offers are fixed at $100,000 to $550,000 by disease tier and exposure length, averaging about $294,000 among approved offers. AFFF personal injury projections run from roughly $20,000 to $500,000 or more. Depo-Provera estimates cluster between $150,000 and $1 million.
Are mass tort settlements larger than class action settlements?
Generally yes, and by a wide margin for seriously injured claimants. Class action members share a common fund and often receive between $10 and $500. Mass tort plaintiffs file individually and are valued on their own diagnosis, exposure and damages.
How long does it take to get paid?
Two to four years from filing to first payment is typical, and large programs distribute in waves over several additional years. The 3M settlement was announced in August 2023 and was still paying deferred-program claims in 2026.
How much do lawyers take from a mass tort settlement?
Contingency fees typically run 33% to 40%, plus a common benefit holdback imposed by the MDL court (9% in the 3M program), plus case costs and healthcare liens. A $250,000 gross award commonly nets a claimant somewhere between $100,000 and $140,000.
Which mass torts have the highest settlement amounts?
Mesothelioma and asbestos remain the highest-value category. Camp Lejeune Tier 1 cancers, well-documented talc ovarian cancer claims, Depo-Provera meningioma cases requiring surgery, and AFFF kidney and testicular cancer claims occupy the next band.
Do settlement amounts vary by state?
Indirectly, yes. Comparative negligence rules, damages caps, statutes of limitation and repose, and venue jury history all change what an otherwise identical claim is worth. Pure comparative negligence states support the highest blended values in our dataset.
Are mass tort settlements taxable?
Compensatory damages for physical injury or physical sickness are generally excluded from gross income under federal tax law, while punitive damages and interest are generally taxable. Allocation matters and rules vary. This is not tax advice; claimants should consult a tax professional.
How should a law firm use settlement amounts to price a campaign?
Work backward from cost per retained case, not cost per lead, then apply a compensable rate of 50–60%, subtract the common benefit holdback, and carry the result across a 24 to 48 month funding horizon. Use the calculator above to model your own assumptions.
Get Qualified Mass Tort Leads with Injury Case Claims
Settlement amounts only translate into revenue if the cases behind them survive medical record review. That is where most mass tort programs lose money, and it is where our screening is built to add value. The team at Injury Case Claims has over 15 years of experience in plaintiff acquisition, and every campaign is backed by a 7-day full-replacement guarantee — investment protection no other lead provider in this space offers.
We run mass tort, MVA and personal injury campaigns across the active 2026 docket, including Depo-Provera, talcum powder, hair relaxer, asbestos, Ozempic, Roblox and social media addiction. Reach us through the contact page, by email, or directly at (800) 889-1679.
Want to level the playing field?
Subscribe and get our monthly settlement and CPL benchmark report in your inbox.
Michael Taylor
Founder & Chief Executive Officer, Injury Case ClaimsMichael has worked in plaintiff acquisition since 2009, building mass tort and MVA campaigns for law firms in all 50 states across every major MDL of the past fifteen years. He tracks JPML filings, FDA actions and bellwether outcomes monthly, and compiles this settlement report from court records, government filings and Injury Case Claims' own campaign data spanning 62,500+ delivered claimants.
Disclaimer: This report is published by Injury Case Claims, LLC, a legal marketing and plaintiff acquisition company. It is not a law firm and does not provide legal, tax or financial advice. Settlement figures described here are drawn from public court records, government filings, company announcements and published attorney estimates. They are informational estimates, not predictions or guarantees, and no specific outcome is promised in any case. Prior results do not guarantee a similar outcome. Individuals who believe they may have a claim should consult a licensed attorney in their jurisdiction.
